A Cell-Based ADCC Bioassay Comparison

The surge in interest for developing therapeutic antibodies in the last few years has led to increased demand for reliable cell-based assays to assess the ability of these antibodies to elicit ADCC.

In this white paper, we present data on the quantification of ADCC using cell-based iLite ADCC bioassays. In addition, we compare this technology to a traditional method based on NFAT effector cells and wild-type target cells.

When comparing iLite ADCC bioassays against the assays of a leading competitor that uses traditional NFAT only effector cells co-cultured with wild-type target cells, the iLite assays show dramatically higher ADCC activity.

The extra sensitivity of the iLite assays can be of great importance in some studies, such as when comparing Fc glycosylation patterns between mAbs.

When using effector cells from one manufacturer and target cells from the other, we found that iLite effector cells were performing better than those of a leading competitor in terms of of dynamic range and signal-to-noise ratio when using either iLite target cells or SK-BR3 target cells.